Stereotaxis Inc. (Seite 10)
eröffnet am 23.11.19 11:31:56 von
neuester Beitrag 19.05.23 14:50:52 von
neuester Beitrag 19.05.23 14:50:52 von
Beiträge: 132
ID: 1.315.889
ID: 1.315.889
Aufrufe heute: 0
Gesamt: 5.348
Gesamt: 5.348
Aktive User: 0
ISIN: US85916J4094 · WKN: A1J09L · Symbol: RJR1
1,9600
EUR
-2,97 %
-0,0600 EUR
Letzter Kurs 09:31:05 Tradegate
Neuigkeiten
22.04.24 · globenewswire  |
04.03.24 · globenewswire |
04.03.24 · globenewswire |
22.02.24 · globenewswire |
20.02.24 · globenewswire |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,6300 | +10.096,63 | |
| 2,1400 | +42,67 | |
| 1,5100 | +39,17 | |
| 0,7400 | +36,63 | |
| 3,5100 | +27,64 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,6250 | -17,12 | |
| 2,0500 | -28,32 | |
| 2,5900 | -32,11 | |
| 2,4100 | -51,51 | |
| 4,1700 | -62,50 |
Beitrag zu dieser Diskussion schreiben
Feedback
Alexander Romanov, Herzchirurg an der Meshalkin-Klinik, erhielt ein Präsidialstipendium für junge Wissenschaftler, die ihre Wirksamkeit bei der Behandlung gefährlicher Herzrhythmusstörungen bei Kindern und Erwachsenen mit angeborenen Herzfehlern steigern wollten. Sie werden mit dem einzigen Robotersystem in Russland operiert. Dr. Romanov wird zusammen mit drei Kollegen 2 Millionen Rubel erhalten, um die Studie fortzusetzen - eine Million im Jahr 2020 und eine Million im Jahr 2021.
- Wir konzentrierten uns auf eine komplexe Kategorie von Patienten mit angeborenen Herzerkrankungen und Herzrhythmusstörungen. Bei normaler Anatomie des Herzens treten bestimmte Gefäße aus und fließen in bestimmte Kammern. Bei angeborenen Fehlern ist alles verwirrt, dies ist ein Mosaik, eine Art Labyrinth, in das ein großes Hauptgefäß nur schwer hineinfließt. Bei solchen Patienten sind Rhythmusstörungen komplex. Komplexe Anatomie erschwert die Behandlung. Am häufigsten sind dies verlassene Patienten “, sagte der Chirurg Alexander Romanov.
Nach Angaben des Arztes gibt es in Russland derzeit zwei Robotersysteme zur Behandlung von Herzrhythmusstörungen - in Nowosibirsk und Moskau, die jedoch in der Hauptstadt nicht funktionieren. In der Meshalkin-Klinik werden seit Herbst 2016 Operationen durchgeführt, die über drei Jahre lang mehr als 700 Patienten geholfen haben. Jährlich werden in der Meshalkin-Klinik 40–50 Erwachsene und Kinder mit komplexen Herzfehlern operiert, die ebenfalls an Herzrhythmusstörungen leiden. Chirurgen operieren nicht nur an den Bewohnern Sibiriens, auch Moskauer wenden sich an die Meshalkin-Klinik. Die Ärzte hoffen, dass die Anzahl der Operationen in Zukunft zunehmen wird.
- Bei einem Robotersystem werden die Elektroden manuell im Herzen des Patienten installiert - von Hand. Anschließend wird die gesamte Operation, die wir im Kontrollraum sitzen, mithilfe der Computermaus, mit der wir diese Elektroden bewegen, ausgeführt. Technologisch gesehen sind diese Elektroden sehr flexibel, sagen sie über sie aus - wie Nudeln kann man sie zu einem Knoten zusammenbinden. Diese schwierige Kategorie von Patienten weist Bereiche im Herzen auf, die schwer zu erreichen und zu beeinflussen sind. "Wir haben Erfahrungen mit der Behandlung von Patienten ohne Herzfehler gesammelt, nach denen wir eine Reihe komplexer Patienten operierten und sehr gute Ergebnisse in Bezug auf Effizienz und Sicherheit erzielten", sagte der Herzchirurg
https://news.ngs.ru/more/66468841/
- Wir konzentrierten uns auf eine komplexe Kategorie von Patienten mit angeborenen Herzerkrankungen und Herzrhythmusstörungen. Bei normaler Anatomie des Herzens treten bestimmte Gefäße aus und fließen in bestimmte Kammern. Bei angeborenen Fehlern ist alles verwirrt, dies ist ein Mosaik, eine Art Labyrinth, in das ein großes Hauptgefäß nur schwer hineinfließt. Bei solchen Patienten sind Rhythmusstörungen komplex. Komplexe Anatomie erschwert die Behandlung. Am häufigsten sind dies verlassene Patienten “, sagte der Chirurg Alexander Romanov.
Nach Angaben des Arztes gibt es in Russland derzeit zwei Robotersysteme zur Behandlung von Herzrhythmusstörungen - in Nowosibirsk und Moskau, die jedoch in der Hauptstadt nicht funktionieren. In der Meshalkin-Klinik werden seit Herbst 2016 Operationen durchgeführt, die über drei Jahre lang mehr als 700 Patienten geholfen haben. Jährlich werden in der Meshalkin-Klinik 40–50 Erwachsene und Kinder mit komplexen Herzfehlern operiert, die ebenfalls an Herzrhythmusstörungen leiden. Chirurgen operieren nicht nur an den Bewohnern Sibiriens, auch Moskauer wenden sich an die Meshalkin-Klinik. Die Ärzte hoffen, dass die Anzahl der Operationen in Zukunft zunehmen wird.
- Bei einem Robotersystem werden die Elektroden manuell im Herzen des Patienten installiert - von Hand. Anschließend wird die gesamte Operation, die wir im Kontrollraum sitzen, mithilfe der Computermaus, mit der wir diese Elektroden bewegen, ausgeführt. Technologisch gesehen sind diese Elektroden sehr flexibel, sagen sie über sie aus - wie Nudeln kann man sie zu einem Knoten zusammenbinden. Diese schwierige Kategorie von Patienten weist Bereiche im Herzen auf, die schwer zu erreichen und zu beeinflussen sind. "Wir haben Erfahrungen mit der Behandlung von Patienten ohne Herzfehler gesammelt, nach denen wir eine Reihe komplexer Patienten operierten und sehr gute Ergebnisse in Bezug auf Effizienz und Sicherheit erzielten", sagte der Herzchirurg
https://news.ngs.ru/more/66468841/
People who know this area have written that the stock should be in the $15-20 range at the moment. Seeking Alpha has 3 or 4 bullish items.
Here's just one of many, from a stxs owner.
Stereotaxis - Acquisition of Robotic Vascular Peer underlines substantial upside potential, private placement again positive
Sep. 3, 2019 2:05 PM ET | 15 comments | About: Stereotaxis, Inc. (STXS), Includes: CVRS, ISRG, JNJ, PHG, RCEL, SMMNY
Overlooked and understaffed
Overlooked and understaffed
value, special situations, only long
(556 followers)
Summary
The active M & A environment in the medical robotics segment continues with the USD 1.1 billion acquisition of Corindus Vascular Robotics from Stereotaxis by Siemens Healthineers.
The CVRS acquisition confirms a significant market potential for robotics in the cardiac and neurovascular market, and the P / S multiples paid for it would imply a valuation of USD 13 to USD 26 / share for STXS.
According to the latest of over 350 peer-reviewed publications, the stereotaxis robotic platform now offers trifecta of clinical superiority, safety and speed.
Securing $25 million through private placement of intelligent healthcare funds, including the Redmile Group, provides the foundation for faster growth and expansion of indications.
Stereotaxis recently discussed the possibility of taking action against cancer for the first time. This is remarkable after J & J's USD 5 billion acquisition of Auris Health.
Active M & A environment in the robotic medical devices segment continues; Following J & J's acquisition of Auris Health in February 2019 for $5 billion, Siemens Healthineers is acquiring the robotic Peer Corindus Vascular Robotics (NYSEMKT: CVRS) from Stereotaxis for $1.1 billion. Stereotaxis in particular has similar (if not greater) growth opportunities ahead of it
In the section Evaluation / Summary of the previous SA article from May 2019 entitled Stereotaxis: Well positioned to become the "intuitive surgery of endovascular surgery" with Genesis Launch and own catheter development, Corindus Vascular Robotics was highlighted as one of two robots in the trade with medical colleagues with a significantly higher P / sales multiple than Stereotaxis (OTC: STXS). Since this analysis, Siemens Healthineers (OTCPK: SMMNY) has offered $1.1 billion for the acquisition of Corindus, making the current valuation of Stereotaxis even more attractive, especially in view of higher revenues, lower cash burn, proximity to profitability, larger installation base and similar factors (if applicable) not greater) growth opportunity ahead.
Placing comparable P / S multiples on Stereotaxis for what Corindus was acquired for (102x, ~ 61X and ~ 38X for actual GJ 18, estimated GJ 19 and estimated GJ 20 respectively) would result in STXS today being valued at between USD 13 and USD 26 / share. This valuation range takes into account the higher Stereotaxis shares issued, which now amount to approximately 114 million shares after the private placement of USD 25 million led by the Redmile Group.
Clearly, these valuation levels reflect the take-out price of a robot and this section does not suggest that Stereotaxis is worth these levels based on its fundamentals today. However, the future growth opportunities for Stereotaxis are likely to be as great, if not greater, than for Corindus and Auris Health, which J & J (JNJ) acquired for USD 5 billion in February 2019.
As discussed in the earlier SA article, stereotaxis has broad regulatory clearance across the entire vascular system, including neurovascular, peripheral anatomy and coronary vascular procedures, making the overall addressable market significant. The robot's unique "pull" action mechanism uses magnetism to control devices throughout the vasculature with greater precision and safety, unlike other robotic and manual approaches that use a "push" action mechanism. This magnetic "pull" approach allows access to areas of the vascular system that would otherwise be inaccessible using "push" approaches, including robotic and manual.
Given this significant market opportunity and the superior approach, I believe Stereotaxis can achieve a value closer to $13-16 USD/share in an acquisition scenario, based on similar forward P/sales ratios for GJ2019 and GJ2020, which Corindus will receive at $1.1 billion Taking into account the $5 billion ($3.4 billion upfront) that J & J paid for Auris Health earlier this year, the price is even
Translated with www.DeepL.com/Translator (free version)
Here's just one of many, from a stxs owner.
Stereotaxis - Acquisition of Robotic Vascular Peer underlines substantial upside potential, private placement again positive
Sep. 3, 2019 2:05 PM ET | 15 comments | About: Stereotaxis, Inc. (STXS), Includes: CVRS, ISRG, JNJ, PHG, RCEL, SMMNY
Overlooked and understaffed
Overlooked and understaffed
value, special situations, only long
(556 followers)
Summary
The active M & A environment in the medical robotics segment continues with the USD 1.1 billion acquisition of Corindus Vascular Robotics from Stereotaxis by Siemens Healthineers.
The CVRS acquisition confirms a significant market potential for robotics in the cardiac and neurovascular market, and the P / S multiples paid for it would imply a valuation of USD 13 to USD 26 / share for STXS.
According to the latest of over 350 peer-reviewed publications, the stereotaxis robotic platform now offers trifecta of clinical superiority, safety and speed.
Securing $25 million through private placement of intelligent healthcare funds, including the Redmile Group, provides the foundation for faster growth and expansion of indications.
Stereotaxis recently discussed the possibility of taking action against cancer for the first time. This is remarkable after J & J's USD 5 billion acquisition of Auris Health.
Active M & A environment in the robotic medical devices segment continues; Following J & J's acquisition of Auris Health in February 2019 for $5 billion, Siemens Healthineers is acquiring the robotic Peer Corindus Vascular Robotics (NYSEMKT: CVRS) from Stereotaxis for $1.1 billion. Stereotaxis in particular has similar (if not greater) growth opportunities ahead of it
In the section Evaluation / Summary of the previous SA article from May 2019 entitled Stereotaxis: Well positioned to become the "intuitive surgery of endovascular surgery" with Genesis Launch and own catheter development, Corindus Vascular Robotics was highlighted as one of two robots in the trade with medical colleagues with a significantly higher P / sales multiple than Stereotaxis (OTC: STXS). Since this analysis, Siemens Healthineers (OTCPK: SMMNY) has offered $1.1 billion for the acquisition of Corindus, making the current valuation of Stereotaxis even more attractive, especially in view of higher revenues, lower cash burn, proximity to profitability, larger installation base and similar factors (if applicable) not greater) growth opportunity ahead.
Placing comparable P / S multiples on Stereotaxis for what Corindus was acquired for (102x, ~ 61X and ~ 38X for actual GJ 18, estimated GJ 19 and estimated GJ 20 respectively) would result in STXS today being valued at between USD 13 and USD 26 / share. This valuation range takes into account the higher Stereotaxis shares issued, which now amount to approximately 114 million shares after the private placement of USD 25 million led by the Redmile Group.
Clearly, these valuation levels reflect the take-out price of a robot and this section does not suggest that Stereotaxis is worth these levels based on its fundamentals today. However, the future growth opportunities for Stereotaxis are likely to be as great, if not greater, than for Corindus and Auris Health, which J & J (JNJ) acquired for USD 5 billion in February 2019.
As discussed in the earlier SA article, stereotaxis has broad regulatory clearance across the entire vascular system, including neurovascular, peripheral anatomy and coronary vascular procedures, making the overall addressable market significant. The robot's unique "pull" action mechanism uses magnetism to control devices throughout the vasculature with greater precision and safety, unlike other robotic and manual approaches that use a "push" action mechanism. This magnetic "pull" approach allows access to areas of the vascular system that would otherwise be inaccessible using "push" approaches, including robotic and manual.
Given this significant market opportunity and the superior approach, I believe Stereotaxis can achieve a value closer to $13-16 USD/share in an acquisition scenario, based on similar forward P/sales ratios for GJ2019 and GJ2020, which Corindus will receive at $1.1 billion Taking into account the $5 billion ($3.4 billion upfront) that J & J paid for Auris Health earlier this year, the price is even
Translated with www.DeepL.com/Translator (free version)
1. It is now finally cash flow positive (just barely), which 95 percent of small biotechs and med techs never attain, or come close.
2. New young CEO rescued it, and is obviously talented and committed and not interested in lining his own pockets whatsoever.
3. The technology appears best of breed, an obviously important thing for a variety of reasons. 100 patents, wide moat, not some kid stock that just started 2 or 3 or 4 years ago.
4. As the presentation says, the market is 4B per year, and growing 10 percent per year. (heck, even the growth annually, starting at 400 million global market aint bad!). The company currently has just 1 percent of the existing market.
5. Has a nice fat cash balance of 34 million, so for the next couple years you dont have to worry about a secondary. The company has been extremely frugal to date in its spending, but this cash balance lets it now market the new machine with some muscles, unlike at any point in this companys history.
6. The mews announcements the last 9 months show the company is partnering with other best of breeds, while advancing its latest flagship product which was CEd in Europe last year. It is now being marketed there. The FDA approval process in America seems very advanced. Possible approval in February, in fact probable approval as this is the end of the 90 period. The fda recommended catch up application sailed through very quickly with approval. I would say probable approval in february but even if FDA asks for more info, eventually the new flagship is gonna be approved, there is no question whatsoever, and the Europeans have already approved it. I think the stock lurches much higher when FDA approves it.
7. The company is already cash flow positive and has a very stable existing customer base of 110 existing clients, all of which will buy the new flagship.
8. The company also has, most wonderfully, the razor blade model as well, and seems in sum like a tiny ISRG.
9. Recent comparable sales, per SA authors, suggest it is now worth between 15 and possibly as high as 25 bucks. And the stock price is clearly being bought without a doubt.
10. I think the first sale of the flagship, which could be in europe any week now, will also lurch the share price much higher.
11. Insiders hold a ton of the stock, another key marker, and institutions have been buying without any question, steadily.
12. Personally, I like all of this, a neglected company with best of breed technology, that had poor leadership, with a new ceo who is not greedy, has the energy of a young guy, is totally committed with his own money and his familys money, with funds now deeply committed, with high margins (not like a drug but 60 to 80 recurring margins is fairly hard to beat, with a huge patent protection propriety technology, etc.......IF THIS WERE A BIOTECH THIS STOCK WOULD HAVE A BILLION DOLLAR MARKET CAP
13. Margins are either 60 or 80 percent, depending on whether it is a new system purchase, or simply the razor blades later.
14. If you look at their twitter page, it is abundantly clear that they have an amazing product, and that physicians around the world are thrilled with it. These docs know the competition quite well and none say they would ever any longer use it. The Stxs product(s) is superior, and it is logical that it would be superior with the companys proprietary approach, and most important, it is safe for docs and operating room staff to use, and the competitions stuff is unsafe and there are stats on this to back up this claim.
15.There is the suggestion, made now by the CEO several times, that they are also formulating partners to attack 2 or 3 other multi billion dollar markets, lung and peripheral and neuro surgical. This is down the line obviously but once the new machine is selling, as it will and as it must, I can see them partnering it with a giant for these other markets, at some point this year or next year.
16. My sense in medical robotics is that when you hit it, you really hit it big. There are so few of these companies around that are truly good and they naturally will garner an amazing premium due to the incredible futures they will have, if they are real. Understandably the robotics market is red hot if the company is real.
17. Last but not least, from a macro investing standpoint, every tom dick and harry fund manager is worried about what the business professor ninnies call late cycle investing.
And it is true I suppose that based purely on the past few economic cycles, some can say equities now are Late Cycle, a new cool word or phrase. But from a science perspective, all this is nonsense. These prior analogy markets are merely anectdotal, not predictive scientifically, Big Difference. It is sort of like betting football. You will see all these oddsmakers and gambliing junkies saying, you know the forty niners should win because the last 9X they played this team on the road and were away dogs, they have won 7 of 9 of these games. So the bet for the niners is obviously correct. .....WRONG...the teams had probably almost completely different players, in fact both teams. What happened in the past between teams which had guys who are now completely retired is irrelevant to the current players and teams.
So while I am invested in gold miners, and love gold now as an investment, there is no way if I am right, that gold will go up the way a true robotics company will. Just compare isrg with a gold index the past 2 decades. NO comparison to put it mildly.
And my point is, a robotics company pretty much does not give 2 scheats about economic cycles, or late stage investing, if there is such a thing. It is gonna go up wildly regardless.
QUESTION: Have I forgotten anything? This one appears very real. The revamped corp. presentation is impressive.
check out their twitter page, you will see very very happy customers and the sky is the limit type of thing. 100,000 patients treated to date, and hundreds of docs have used it so far, worldwide. No complaints. Nobody going back to the old standardized outmoded (?) manual push method.
2. New young CEO rescued it, and is obviously talented and committed and not interested in lining his own pockets whatsoever.
3. The technology appears best of breed, an obviously important thing for a variety of reasons. 100 patents, wide moat, not some kid stock that just started 2 or 3 or 4 years ago.
4. As the presentation says, the market is 4B per year, and growing 10 percent per year. (heck, even the growth annually, starting at 400 million global market aint bad!). The company currently has just 1 percent of the existing market.
5. Has a nice fat cash balance of 34 million, so for the next couple years you dont have to worry about a secondary. The company has been extremely frugal to date in its spending, but this cash balance lets it now market the new machine with some muscles, unlike at any point in this companys history.
6. The mews announcements the last 9 months show the company is partnering with other best of breeds, while advancing its latest flagship product which was CEd in Europe last year. It is now being marketed there. The FDA approval process in America seems very advanced. Possible approval in February, in fact probable approval as this is the end of the 90 period. The fda recommended catch up application sailed through very quickly with approval. I would say probable approval in february but even if FDA asks for more info, eventually the new flagship is gonna be approved, there is no question whatsoever, and the Europeans have already approved it. I think the stock lurches much higher when FDA approves it.
7. The company is already cash flow positive and has a very stable existing customer base of 110 existing clients, all of which will buy the new flagship.
8. The company also has, most wonderfully, the razor blade model as well, and seems in sum like a tiny ISRG.
9. Recent comparable sales, per SA authors, suggest it is now worth between 15 and possibly as high as 25 bucks. And the stock price is clearly being bought without a doubt.
10. I think the first sale of the flagship, which could be in europe any week now, will also lurch the share price much higher.
11. Insiders hold a ton of the stock, another key marker, and institutions have been buying without any question, steadily.
12. Personally, I like all of this, a neglected company with best of breed technology, that had poor leadership, with a new ceo who is not greedy, has the energy of a young guy, is totally committed with his own money and his familys money, with funds now deeply committed, with high margins (not like a drug but 60 to 80 recurring margins is fairly hard to beat, with a huge patent protection propriety technology, etc.......IF THIS WERE A BIOTECH THIS STOCK WOULD HAVE A BILLION DOLLAR MARKET CAP
13. Margins are either 60 or 80 percent, depending on whether it is a new system purchase, or simply the razor blades later.
14. If you look at their twitter page, it is abundantly clear that they have an amazing product, and that physicians around the world are thrilled with it. These docs know the competition quite well and none say they would ever any longer use it. The Stxs product(s) is superior, and it is logical that it would be superior with the companys proprietary approach, and most important, it is safe for docs and operating room staff to use, and the competitions stuff is unsafe and there are stats on this to back up this claim.
15.There is the suggestion, made now by the CEO several times, that they are also formulating partners to attack 2 or 3 other multi billion dollar markets, lung and peripheral and neuro surgical. This is down the line obviously but once the new machine is selling, as it will and as it must, I can see them partnering it with a giant for these other markets, at some point this year or next year.
16. My sense in medical robotics is that when you hit it, you really hit it big. There are so few of these companies around that are truly good and they naturally will garner an amazing premium due to the incredible futures they will have, if they are real. Understandably the robotics market is red hot if the company is real.
17. Last but not least, from a macro investing standpoint, every tom dick and harry fund manager is worried about what the business professor ninnies call late cycle investing.
And it is true I suppose that based purely on the past few economic cycles, some can say equities now are Late Cycle, a new cool word or phrase. But from a science perspective, all this is nonsense. These prior analogy markets are merely anectdotal, not predictive scientifically, Big Difference. It is sort of like betting football. You will see all these oddsmakers and gambliing junkies saying, you know the forty niners should win because the last 9X they played this team on the road and were away dogs, they have won 7 of 9 of these games. So the bet for the niners is obviously correct. .....WRONG...the teams had probably almost completely different players, in fact both teams. What happened in the past between teams which had guys who are now completely retired is irrelevant to the current players and teams.
So while I am invested in gold miners, and love gold now as an investment, there is no way if I am right, that gold will go up the way a true robotics company will. Just compare isrg with a gold index the past 2 decades. NO comparison to put it mildly.
And my point is, a robotics company pretty much does not give 2 scheats about economic cycles, or late stage investing, if there is such a thing. It is gonna go up wildly regardless.
QUESTION: Have I forgotten anything? This one appears very real. The revamped corp. presentation is impressive.
check out their twitter page, you will see very very happy customers and the sky is the limit type of thing. 100,000 patients treated to date, and hundreds of docs have used it so far, worldwide. No complaints. Nobody going back to the old standardized outmoded (?) manual push method.
Trading Spotlight
Durchsuchen
